Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
复制标题
DOI:
10.1016/j.cell.2022.03.019
复制
发表时间:
2022-04-28
期刊:
影响因子:
64.5
通讯作者:
Chiu CY
中科院分区:
文献类型:
--
作者:
Servellita V;Syed AM;Morris MK;Brazer N;Saldhi P;Garcia-Knight M;Sreekumar B;Khalid MM;Ciling A;Chen PY;Kumar GR;Gliwa AS;Nguyen J;Sotomayor-Gonzalez A;Zhang Y;Frias E;Prostko J;Hackett J Jr;Andino R;Wadford DA;Hanson C;Doudna J;Ott M;Chiu CY
Virus-like particle (VLP) and live virus assays were used to investigate neutralizing immunity against Delta and Omicron SARS-CoV-2 variants in 259 samples from 128 vaccinated individuals. Following Delta breakthrough infection, titers against WT rose 57-fold and 3.1-fold compared with uninfected boosted and unboosted individuals, respectively, versus only a 5.8-fold increase and 3.1-fold decrease for Omicron breakthrough infection. Among immunocompetent, unboosted patients, Delta breakthrough infections induced 10.8-fold higher titers against WT compared with Omicron (p = 0.037). Decreased antibody responses in Omicron breakthrough infections relative to Delta were potentially related to a higher proportion of asymptomatic or mild breakthrough infections (55.0% versus 28.6%, respectively), which exhibited 12.3-fold lower titers against WT compared with moderate to severe infections (p = 0.020). Following either Delta or Omicron breakthrough infection, limited variant-specific cross-neutralizing immunity was observed. These results suggest that Omicron breakthrough infections are less immunogenic than Delta, thus providing reduced protection against reinfection or infection from future variants. In comparing breakthrough infections from the SARS-CoV-2 Delta and Omicron variants, the latter, though milder than Delta infections, were associated with lower antibody titers and limited cross-neutralizing immunity, suggesting reduced protection against reinfection or infection from a future variant.
登录
查看更多内容
DOI:
10.1016/s0140-6736(22)00017-4
发表时间:
2022-01-29
期刊:
Lancet (London, England)
影响因子:
--
作者:
Wolter N;Jassat W;Walaza S;Welch R;Moultrie H;Groome M;Amoako DG;Everatt J;Bhiman JN;Scheepers C;Tebeila N;Chiwandire N;du Plessis M;Govender N;Ismail A;Glass A;Mlisana K;Stevens W;Treurnicht FK;Makatini Z;Hsiao NY;Parboosing R;Wadula J;Hussey H;Davies MA;Boulle A;von Gottberg A;Cohen C
通讯作者:
Cohen C
DOI:
10.1038/s41577-022-00676-6
发表时间:
2022-03
期刊:
Nature reviews. Immunology
影响因子:
--
作者:
Flemming A
通讯作者:
Flemming A
DOI:
10.1101/2021.08.09.21261290
发表时间:
2022-01-07
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Gilbert, Peter B;Montefiori, David C;Koup, Richard A
通讯作者:
Koup, Richard A
影响因子:
30.3
作者:
Case, James Brett;Rothlauf, Paul W.;Whelan, Sean P. J.
通讯作者:
Whelan, Sean P. J.
影响因子:
82.9
作者:
Gruell H;Vanshylla K;Tober-Lau P;Hillus D;Schommers P;Lehmann C;Kurth F;Sander LE;Klein F
通讯作者:
Klein F